Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Trastuzumab | Trastuzumab Inhibitor. Uses: Scientific use. Product Category: T9912. CAS No. 180288-69-1. |  |
| Trastuzumab | Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Anti-Human HER2, Humanized Antibody. CAS No. 180288-69-1. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-P9907. |  |
| Trastuzumab | Trastuzumab is a monoclonal antibody drug for the treatment of breast cancer which is HER2 receptor positive. It acts via binding to HER2 receptor to suppress cell duplication. Uses: The treatment of her2 receptor positive breast cancer. Synonyms: Herceptin; RhuMab HER2; Anti HER2, Ig gamma-1 chain C region; Recombinant humanized anti-HER2 antibody; IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer. CAS No. 180288-69-1. Molecular formula: C10H14N6O5. Mole weight: 145kda. |  |
| Trastuzumab (anti-HER2) | Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Anti-Human HER2, Humanized Antibody (PBS). CAS No. 180288-69-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9907A. | |
| Trastuzumab deruxtecan | Trastuzumab deruxtecan (DS-8201a) is an anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: DS-8201; DS-8201a. CAS No. 1826843-81-5. Pack Sizes: 1 mg; 5 mg. Product ID: HY-138298A. | |
| Trastuzumab deruxtecan (solution) | Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: DS-8201 (solution); DS-8201a (solution). CAS No. 1826843-81-5. Pack Sizes: 1 mg (10 mg/mL * 100 μL in Aqueous solution); 5 mg (10 mg/mL * 500 μL in Aqueous solution). Product ID: HY-138298. | |
| Trastuzumab duocarmazine | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: (vic)-Trastuzumab duocarmazine. CAS No. 1642152-40-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99547. | |
| Trastuzumab emtansine | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate ( ADC ) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Ado-Trastuzumab emtansine; PRO132365; T-DM 1. CAS No. 1018448-65-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9921. | |
| Trastuzumab emtansine | Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surface surfaces. Upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. Grades: 95%. CAS No. 1018448-65-1. Molecular formula: C6448H9948N1720O2012S44· (C47H62ClN4O13S)n. | |
| Trastuzumab emtansine (solution) | Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution). CAS No. 1018448-65-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9921A. | |
| Trastuzumab impurity 1 | Trastuzumab impurity 1. Uses: For analytical and research use. Group: Impurity standards. CAS No. 130878-68-1. Molecular Formula: C24H24N2O6. Mole Weight: 436.46. Catalog: APB130878681. |  |
| Trastuzumab impurity 2 | Trastuzumab impurity 2. Uses: For analytical and research use. Group: Impurity standards. CAS No. 159858-22-7. Molecular Formula: C33H39N5O6. Mole Weight: 601.7. Catalog: APB159858227. | |
| Trastuzumab impurity 3 | Trastuzumab impurity 3. Uses: For analytical and research use. Group: Impurity standards. CAS No. 34321-81-8. Molecular Formula: C8H11NO4. Mole Weight: 185.18. Catalog: APB34321818. | |
| Trastuzumab rezetecan | Trastuzumab rezetecan (SHR-A1811) is a HER2 -targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SHR-A1811. CAS No. 2924909-11-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-164762. | |
| a-Solamargine | This compound is a cytotoxic glycoalkaloid and a commonly found secondary metabolite in the plants of the genus Solanum. Solamargine penetrates cell membrane, inhibits growth of tumoral cell lines and induces apoptosis at low micromolar concentrations. It also sensitises cancer cell lines to the treatment with chemotherapeutic agents, such as cisplatin, epirubicin and trastuzumab. The compound was seen to inhibit P-glycoprotein in neuroblastoma cell line. Group: Other alkaloids. Alternative Names: Solasodine-L-rhamnosido-D-glucoside(3b,22a,25R)-Spirosol-5-en-3-yl O-6-deoxy-a-L-mannopyranosyl-(1?2)-O-[6-deoxy-a-L-mannopyranosyl -(1?4)]-b-D-glucopyranoside. CAS No. 20311-51-7. Molecular formula: C45H73NO15. Mole weight: 868.06 g/mol. Canonical SMILES: C[C@@H]1CC[C@@]2 ([C@H] ([C@H]3[C@@H] (O2)C[C@@H]4[C@@]3 (CC[C@H]5[C@H]4CC=C6[C@@]5 (CC[C@@H] (C6)O[C@H]7[C@@H] ([C@H] ([C@@H] ([C@H] (O7)CO)O[C@H]8[C@@H] ([C@@H] ([C@H] ([C@@H] (O8)C)O)O)O)O)O[C@H]9[C@@H] ([C@@H] ([C@H] ([C@@H] (O9)C)O)O)O)C)C)C)NC1. Catalog: ACM20311517-1. |  |
| Deruxtecan | Deruxtecan analog is a drug-linker conjugate for antibody-drug conjugate (ADC). Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody-drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThHER2) cells. DS-8201a is currently in clinical trials. Synonyms: Deruxtecan Analog; Deruxtecan, Trastuzumab deruxtecan; DS-8201a; DS8201a; DS 8201a; Exatecan derivative; DX-8951 derivative; DX 8951; DX8951; N-[6-(2, 5-Dioxo-2, 5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S, 9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10, 13-dioxo-2, 3, 9, 10, 13, 15-hexahydro-1H, 12H-benzo[de]pyrano[3', 4':6, 7]indolizino[1, 2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide. Grades: ≥95%. CAS No. 1599440-13-7. Molecular formula: C52H56FN9O13. Mole weight: 1034.05. | |
| Deruxtecan | Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody-drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThHER2) cells. DS-8201a is currently in clinical trials. Group: Inhibitors. Alternative Names: Deruxtecan, Trastuzumab deruxtecan; DS-8201a; DS8201a; DS 8201a; exatecan derivative; DX-8951 derivative; DX 8951; DX8951. CAS No. 1599440-13-7. Molecular formula: C52H56FN9O13. Mole weight: 1034.07. Appearance: Solid powder. Purity: >98%. IUPACName: Glycinamide, N-[6-(2, 5-dihydro-2, 5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S, 9S)-9-ethyl-5-fluoro-2, 3, 9, 10, 13, 15-hexahydro-9-hydroxy-4-methyl-10, 13-dioxo-1H, 12Hbenzo[de]pyrano[3', 4':6, 7]indolizino[1, 2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]-. Canonical SMILES: CC[C@@]1 (O) C (OCC2=C1C=C3N (C2=O) CC (C3=NC4=CC (F) =C5C) =C6C4=C5CC[C@@H]6NC (COCNC (CNC ([C@@H] (NC (CNC (CNC (CCCCCN7C (C=CC7=O) =O) =O) =O) =O) CC8=CC=CC=C8) =O) =O) =O) =O. Catalog: ACM1599440137. | |
| GDC-0941 dimethanesulfonate | GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110&gamma. It is a novel selective class I phosphatidylinositol-3-kinase (PI3K) inhibitor. It is designed to bind the ATP-binding pocket of PI3K and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second messenger that transmits PI3K downstream signals. It causes growth inhibition in a variety of cancer cell lines, including A2780, MDA-MB-361, PC3, and U87MG. It also inhibits the growth of trastuzumab-sensitive and -resistant HER2-amplied cancer cells which harbor p110( mutations or PTEN loss. It also reduces tumor volume in different xenograft models. Synonyms: GDC-0941 dimethanesulfonate; GDC 0941 dimethanesulfonate; GDC0941 dimethanesulfonate; Pictilisib dimethanesulfonate; GDC-0941 (2 MeSO3H salt). Grades: >98%. CAS No. 957054-33-0. Molecular formula: C25H35N7O9S4. Mole weight: 705.85. | |
| Herzuma | Herzuma is a biosimilar of trastuzumab approved by EU for the treatment of patients with early breast cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have either receptor tyrosine-protein kinase erbB-2 (HER2) overexpression or HER2 gene amplification. Uses: Cancer therapy. | |
| N-Methyl-L-alanine hydrochloride | N-Methyl-L-alanine is a reactant used in the preparation of site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity. Synonyms: N-Me-L-Ala-OH HCl; N-Methyl-L-alanine; (2S)-2-(methylamino)propanoic acid. Grades: ≥ 98% (TLC). CAS No. 3913-67-5. Molecular formula: C4H9NO2·HCl. Mole weight: 139.62. | |
Our database is helping our users find suppliers everyday.
